A PHARMACOKINETIC POPULATION MODEL FOR CYCLOSPORIN A IN RENAL TRANSPLANT RECIPIENTS : Development of a model for whole blood- and intracellular concentrations by Tran, Truong-Son Manh
  
A PHARMACOKINETIC POPULATION MODEL 
FOR CYCLOSPORIN A IN RENAL TRANSPLANT 
RECIPIENTS 
Development of a model for whole blood- and intracellular 
concentrations 
Trần Mạnh Trường-Sơn 
 
Faculty of Mathemathics and Natural Sciences 
Department of Pharmaceutical Biosciences 
 
School of Pharmacy 
UNIVERSITY IN OSLO 
May 2009 
 2 
AKNOWLEDGEMENT 
 
I would like to thank my supervisor Professor Anders Åsberg for guiding me through 
this past year and a half. Your knowledge and motivating skills have been an 
invaluable contribution and have made this thesis possible. I would also thank Ph.D 
Pål Falck for helping me getting started on this thesis. 
 
Further I would like to thank Trúc Thanh Vân Lê for providing information regarding 
the earlier model and data.  
 
Special thanks for my classmates and friends who have supported me in frustrating 
times, especially Levin Ulrich Løssfelt who I have shared both his and mine positive 
and negative experiences with. 
 
Finally I would like to thank my family, Idunn and all those who stand me close for 
standing by me even though I have not been as available as normal for this last half 
year. You have supported me through long days and weeks and I am forever grateful. 
 
Oslo, May 2009 
 
Trần Mạnh Trường-Sơn
 TABLE OF CONTENT 
AKNOWLEDGEMENT ...................................................................................................................... 2 
TABLE OF CONTENT ........................................................................................................................ 3 
ABBREVIATIONS ............................................................................................................................... 6 
ABSTRACT........................................................................................................................................... 8 
1. INTRODUCTION .................................................................................................................... 10 
1.1 PHARMACOKINETICS .............................................................................................................. 10 
1.1.1 Introduction ................................................................................................................ 10 
1.1.2 Variability ................................................................................................................... 11 
1.1.3 Compartmental theory ................................................................................................ 13 
1.1.4 Population pharmacokinetics ..................................................................................... 13 
2. PHARMACOKINETIC POPULATION MODELING ........................................................ 15 
2.1 INTRODUCTION ...................................................................................................................... 15 
2.1.1 Standard 2-stage approach ......................................................................................... 16 
2.1.2 Naïve pooled data approach ....................................................................................... 16 
2.1.3 Nonlinear mixed-effect model approach ..................................................................... 16 
2.2 NONMEM ............................................................................................................................. 17 
2.2.1 Background ................................................................................................................. 17 
2.2.2 Modelling population PK using NONMEM ................................................................ 18 
2.2.3 How to find the best model using maximum likelihood approach ............................... 20 
3. CYCLOSPORIN A ................................................................................................................... 22 
3.1 HISTORY ................................................................................................................................ 22 
3.2 APPLICATION AND MECHANISM OF ACTION ............................................................................ 22 
3.3 KNOWN PROBLEMS WITH CYCLOSPORIN A ............................................................................ 23 
3.4 ADME OF CSA ..................................................................................................................... 23 
 4 
3.4.1 Administration ............................................................................................................ 23 
3.4.2 Distribution ................................................................................................................ 24 
3.4.3 Metabolism ................................................................................................................. 24 
3.4.4 Elimination ................................................................................................................. 25 
3.5 THERAPEUTIC DRUG MONITORING ......................................................................................... 25 
3.6 POPULATION KINETIC MODELS OF CSA IN LITERATURE ......................................................... 26 
3.7 GOALS OF THE THESIS ........................................................................................................... 26 
4. METHODS AND MATERIALS ............................................................................................ 27 
4.1 MATERIALS FOR THE WHOLE BLOOD MODEL ......................................................................... 27 
4.2 MATERIALS FOR THE WHOLE BLOOD MODEL AND INTRACELLULAR CONCENTRATIONS ......... 29 
4.3 DEVELOPING AND BUILDING THE MODELS ............................................................................. 30 
4.3.1 The whole blood model .............................................................................................. 31 
4.3.2 The whole blood and intracellular model .................................................................. 31 
5. RESULTS ................................................................................................................................. 35 
5.1 RE-ANALYZING FOR COVARIATES FOR THE WHOLE BLOOD MODEL ....................................... 35 
5.2 TESTING FOR INTEROCCACIONAL VARIABILITY ..................................................................... 37 
5.3 COVARIATE ANALYSIS BASED ON VISUAL PREDICTION .......................................................... 38 
5.5 COMPARING THE OLD VERSUS THE NEW MODEL .................................................................... 43 
5.6 THE WHOLE BLOOD AND INTRACELLULAR CONCENTRATIONS ............................................... 44 
5.6.1 Model building results ................................................................................................ 44 
6. DISCUSSIONS ......................................................................................................................... 52 
6.1 RE-ANALYZING FOR COVARIATES FOR CSA PLASMACONCENTRATIONS ................................ 52 
6.2 TESTING FOR INTEROCCASIONAL VARIABILITY FOR THE WHOLE BLOOD MODEL ................... 54 
6.3 WHOLE BLOOD AND INTRACELLULAR MODEL ....................................................................... 55 
7. CONCLUSIONS ...................................................................................................................... 58 
 5 
8. REFERENCES ......................................................................................................................... 59 
9. APPENDIX ............................................................................................................................... 63 
9.1 FORMULAS USED IN DEMOGRAPHICS MODEL .......................................................................... 63 
9.2 PARTIAL INPUT FILE FOR WHOLE BLOOD MODEL .................................................................... 64 
9.3 CONTROL FILE FOR FINAL MODEL WHOLE BLOOD .................................................................. 66 
9.4 INDIVIDUAL FITTING MADE BY R FOR FINAL WHOLE BLOOD MODEL ...................................... 68 
9.5 PARTIAL INPUT FILE FOR WHOLE BLOOD AND INTRACELLULAR MODEL ................................. 77 
9.6 CONTROL FILE FOR FINAL MODEL WHOLE BLOOD AND INTRACELLULAR CONCENTRATIONS .. 80 
9.7 DIAGNOSTIC PLOT MADE BY R FOR WHOLE BLOOD AND INTRACELLULAR MODEL ................. 82 
9.8 DIVERSE FIGURES FOR WHOLE BLOOD AND INTRACELLULAR MODEL WITH A LOWER KA AND OFV 
COMPARING WITH THE FINAL MODEL ................................................................................................ 85 
 
  6 
ABBREVIATIONS 
- 2LL  minus two log likelihood,      
the objective function of 
NONMEM 
ADME absorption, distribution, 
metabolism and 
elimination 
ALAG absorption lagtime 
AUC  area under curve 
BMI  body mass index 
BOV  between occasion 
variability 
C0  trough concentration 
Cn  concentration “n” hours 
post-dose 
CL  clearance 
CsA  Cyclosporine A 
CYP450 cytochrom P450 
DV  dependent variable, 
observed concentration 
DVID  dependent variable 
identification 
F  bioavailability 
FDA  food and drug 
administration (USA) 
FO  first-order 
FOCE  first-order conditional 
estimation 
GOF  goodness of fit 
ID  identification 
IOV  interoccasional 
variability 
IPRED individual predicted 
concentration 
Ka  absorption rate constant 
LBM   lean body mass 
LN  natural logarhytm 
NA  not applicable 
NM-TRAN NONMEM-translator 
NONMEM nonlinear mixed-effect 
modeling 
NPD  naïve pooled data 
OFV   objective function value 
P-gp  P-glycoprotein 
PD  pharmacodynamic 
  7 
PK  pharmacokinetic 
PPK  population 
pharmacokinetic 
PRED  predicted concentration 
Q  inter-compartmental 
clearance 
QOF  quality of fit 
RH  Rikshospital University 
Hospital 
SD  standard deviation 
STS  standard two-stage 
TDM  therapeutic drug 
monitoring 
TV  typical value 
Tx  transplantation 
Vc  central volume 
Vd  distribution volume 
Vp  peripheral volume 
WRES weighted residuals
 
ABSTRACT 
 8 
ABSTRACT 
Background: Cyclosporine A (CsA) has since its introduction in the 1980’s played a 
substantial part of the success in solid organ transplantation. Like many other 
immunosuppressive drugs, CsA has a narrow therapeutic window and a large inter-
individual variability. Drug exposure above the therapeutic window is associated with 
adverse events like nephrotoxicity, infection and cancer while drug exposure below 
will yield a lack of effect and increased risk for acute rejection episodes. Obtaining an 
optimal drug concentration will prevent acute organ rejections and optimize survival 
of the grafts and ultimately the patients. 
The primary aim of this study is to implement a T-cell compartment to an already 
existing whole blood model. Another goal was to further develop the basic whole 
blood model after the inclusion of 20 new patients followed for at least 8 weeks, by 
re-evaluating for relevant covariates and include estimation of interoccasional 
variation in the model. 
Methods: Data was gathered from four separate clinical trials, performed by the 
department of Pharmaceutical Biosciences at the University of Oslo in co-operation 
with the Medical Department at Rikshospitalet, Oslo University Hospital, for the 
whole blood model. In all 70 patients and a total of 1276 whole blood samples were 
included in the whole blood model. 
Of the 70 patients, 20 patients also had intracellular concentrations measured. These 
430 intracellular samples were included in the development of the extended model.  
By using the nonlinear mixed-effect modelling program NONMEM two population 
pharmacokinetic models were developed. 
Results: When re-analyzing for significant covariates, many similar results as earlier 
tested for the whole blood model was found. Age was a significant co-factor on the 
parameters: clearance (CL), absorption (Ka) and compartmental volumes (V1), while 
cytochrom P450 3A5 (CYP3A5) genotype had a significant impact on clearance. The 
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steroid dose and weight influenced the inter-compartmental clearance (Q), while BMI 
had an effect on volume (V1) and absorption (Ka). Interoccasional variability was 
found significant on the parameter V2, and included in the final model. 
An intracellular population pharmacokinetic kinetic (PPK) model was developed for 
CsA. The concentrations were homogenized to the same unit (ng/ml), by estimating 
the T-lymphocyte volume, and LN-transformed because of the large concentration 
range difference. The developed model predicts whole blood and intracellular 
concentrations, but does not predict accurately or stable enough in its current state. 
Conclusion: Two models were developed, one for whole blood concentrations and 
one extended model also including intracellular concentrations of CsA. There is no 
unambiguous answer if the whole blood model gave a significant improvement on the 
already existing model, but the model showed somewhat improvement in the visual 
plots and also included prednisolone and CYP3A5 as a covariate. Interoccasional 
variability was found significant and further included for the whole blood model. The 
whole blood and intracellular model is still in an early stage and needs to be further 
developed, tested for covariates and interoccasional variability, and finally validated.
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1. INTRODUCTION 
1.1 Pharmacokinetics 
1.1.1 Introduction 
Pharmacokinetics (PK) describes the relationship between drug concentrations 
attained in different body compartments with time, during and after drug input. The 
drug level-time relationship is related to adjustable elements such as route of 
administration, dose, dosage form, frequency etc. Pharmacokinetics is simply put 
how the body affects the drug. It differs from pharmacodynamic (PD) which says 
something about the relationship between the drug concentrations effect on the body 
with time. Simply put, PD is how the drug affects the body. [1] 
In order to develop a PK/PD evaluation it would be ideally to take samples from the 
site of action, but because of practical difficulties samples are normally acquired from 
more accessible sites like blood and urine who are two of the most commonly 
sampled fluids.  [1] 
All drugs have a therapeutic window where the drug has optimal effect and 
acceptable side effects. (Figure 1) Below this range the drug exposure is too low to 
give the desired effect, and above the concentration range the drug will result in 
undesired adverse effects. This therapeutic window differs from drug to drug and is 
individual from patient to patient. For drugs with a large therapeutic window it is 
easy to stay in this window, but for drugs with a narrow therapeutic window it can be 
difficult to obtain the ideal concentration where the wanted effect is achieved. [1] 
INTRODUCTION 
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Figure 1. A representation of an optimal dose input so that steady state lies between the minimum 
and maximum levels of the therapeutic window 
1.1.2 Variability 
It is often seen a difference between the expected outcome and true values in PK/PD 
evaluations. This can be attributed to inter-individual variability and residual 
variability. [1] 
Inter-individual variability is the true biological variability that exists between 
subjects. When calculating parameter values based on past experience and research, 
the parameter value for a specific individual will differ from the expected value 
because of true biological differences between individuals. Covariates can account 
for some of this variability, and searching for these factors is an important feature of 
population pharmacokinetics.   
Residual variability is a common name for several variations including intra-
individual variability (variability in between the same patient), interoccasion 
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variability (IOV) (day-to-day or week-to-week) and errors in measurement, dosage 
and modeling. Because the mathematical calculations made are an oversimplification 
of the reality, residual variability can arise. An increase of unexplained random 
variability can cause insecurity when predicting and controlling the drug 
concentrations and this can further lead to a decrease of drug safety and efficacy. It is 
however important to remember that the drug response variability also applies to side 
effects. [2-6] 
Other variabilities in pharmacokinetics that may influence the dose concentration 
relationship are: 
 environmental factors: smoking, diet, exposure to pollutants etc. 
 interactions with other drugs, co-medication 
 physiological factors: pregnancy 
 demographics: gender, age, weight etc. 
 genetic phenotype of polymorphism in cytochrom P450 isoforms that can 
effect both metabolism and clearance of drugs 
 pathophysiological factors: renal- and hepatic impairment, CHD 
 other factors: circadian rhytm, adherence, food effect, timing of meals, 
physical activity, posture and stress 
 
We differ between two different variabilities, fixed- and random effects. Fixed effects 
are properties of each individual that causes them to be different from the average, 
while random effects can not be predicted. Random effect consists of inter-
individuality and residual variability. [3, 7] 
It is well known that individual pharmacokinetic may vary over time. Some of the 
variations can be attributed to physiological processes by means of surrogate 
variables, e.g. serum creatinine, co-medications with known enzyme inhibitors etc. 
Most variability in pharmacokinetic parameters within individuals are however not 
predictable. It could be that the governing processes are not understood or appropriate 
surrogate variables are lacking. Such apparently random intra-individual variability 
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can be arbitrary, but practically, divided into variations interoccasion variability 
(IOV) or sometimes called between-occasions variability (BOV). [8] 
Neglecting IOV may result in a high incidence of statistically significant spurious 
period effects and most importantly, ignoring IOV can lead to a falsely optimistic 
impression of the potential value of therapeutic drug monitoring. [8] 
1.1.3 Compartmental theory 
Human anatomy and physiology is very complex, making it very challenging to 
model how the body uses the drug. It is however possible to simplify the body into 
few compartments in regards of PK modeling. [1] 
A compartment is not a real physiologic or anatomic region. It represents unspecific 
tissue or group of tissues that have similar blood flow and drug affinity. Within each 
compartment the drug is presumed to be uniformly distributed and to reach 
distribution equilibrium simultaneously. [1] 
The simplest model consist of one compartment, which assumes that changes in 
plasma levels of a drug reflect proportional fast changes in tissue drug level. In more 
advanced multi compartment models the drug distributes into the central 
compartment and one or several more tissue/peripheral compartments. The central 
compartment often represents the blood, extracellular fluid and highly perfused 
tissues that rapidly equilibrate with the drug. The tissue/peripheral compartment 
represents tissues where the drug equilibrates to. [1] 
1.1.4 Population pharmacokinetics 
The main goals of population pharmacokinetic (PPK) are to quantitatively assess the 
pharmacokinetic parameters, the inter-individual- and residual variability in drug 
absorption, distribution, metabolism and elimination (ADME). It can be defined as 
the study of variability in plasma drug concentrations between individual 
representatives for the target population group receiving the drug. PPK highly 
contrasts with traditional pharmacokinetics. With PPK the goal is not to homogenize 
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and standardize the patients, whom the data was gathered from, but rather to seek as 
much relevant information as possible and tailor individual dosages based on this.  [3-
5] 
While traditional pharmacokinetic studies rarely account for the random effects, but 
rather PK-averages, population pharmacokinetics has that important feature of 
quantitatively estimating the residual variability in the patient population. This may 
give important information regarding drug efficacy and safety. PPK is therefore often 
used in both drug development and individual dosing regimens. In drug development, 
population pharmacokinetics can help designing dose guidelines. The approach is 
recommended in the US Food and Drug Administration (FDA) guidance for Industry 
as part of the development process. [3, 4, 9] 
PPK makes it possible to collect integrated information on relatively sparse data, 
dense data or from a combination of both. Data can be divided into two groups:  
- Experimental data: Data collected from traditional studies, with a controlled 
design and blood samples i.e. dens data. 
- Observational data: Data gathered through routine clinical care or as a 
supplement for traditional studies. These data are often limited, collected at 
various times and unbalanced. 
 
PPK is most valuable in situations where the drugs have a narrow therapeutic window 
and shows a complex pharmacokinetic relationship. [4, 5]
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2. PHARMACOKINETIC POPULATION MODELING 
2.1 Introduction 
The requirement for population modeling has roots in the need for a system to predict 
pharmacokinetic and/or pharmacodynamic parameters in new patients based on 
patient-characteristics and often limited sampling. Individual predictions of drug 
exposure will increase the chances of successful therapy and reduce the chances for 
dose dependent side effects. [2, 10-12] 
In PPK there are several parametric and nonparametric methods for estimating the 
different parameters. Parametric models have a continuous parameter distribution, 
and the distribution is assumed to be either normal or lognormal. It obtains means and 
standard deviations (SD) of the parameters, and correlations between them. 
Parametric models are able to distinguish inter- and intra-individual and assay error. 
One weakness of this method is that it lacks mathematical consistency, and it makes 
assumptions about the shape of the parameter distribution. [11] 
Nonparametric methods makes no assumptions about the shape of the parameter 
distribution, meaning that no specific parameters such as means and standard 
deviations are used to describe the distribution of the parameters within a population 
a priori. The shape of the distribution is instead exclusively determined from the 
population raw data and can therefore detect any possible subpopulation with other 
distributions. It is mathematical consistent, but it lacks a feature to distinguish the 
various sources of variability. [11] 
Of the most common methods for doing population pharmacokinetic analyses are the 
standard 2-stage (STS) method and the nonlinear mixed-effect model approach, 
which both are parametric, and the naïve pool data approach. [11, 13] 
PHARMACOKINETIC POPULATION MODELING 
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2.1.1 Standard 2-stage approach  
The standard 2-stage approach is traditionally used in data rich situations. It consists 
of two stages where the first phase is to estimate each individual’s PK and/or PD 
parameters from that individual’s dense concentration time data, using a method of 
weighted nonlinear least squares. 
During the second stage the populations mean and variance are derived from 
individual measurements and the relationship between covariates, and the parameters 
explored. 
STS is easy to implement and quick to run, but gives poor prediction of parameters in 
data poor situations. [4, 5, 10, 11, 14] 
2.1.2 Naïve pooled data approach 
In the naïve pooled data (NPD) approach, all data gathered from every individual are 
considered coming from one unique individual. NPD is a general approach and can 
easily deal with experimental data, non-standard data and routine pharmacokinetic 
data. Parameter estimates are obtainable after a unique fitting of all data at 
concurrently. [4, 10] 
NPD may be a good method when inter-individual variability is small. However, 
since the data is recognized as coming from one individual, imbalance and 
confounding correlations may occur. Only mean parameters are given in this 
approach so the inter-individual variability is lost and an imbalance in data per 
individual could lead to biased estimates. [4, 10] 
2.1.3 Nonlinear mixed-effect model approach 
The nonlinear mixed-effect modeling considers the population sample instead of the 
individual. They make foundation to estimate the distribution of parameters, the 
covariates and correlation between them. Similar to the NPD approach, nonlinear 
mixed-effect modeling analyzes data from all individuals simultaneously. The 
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difference is that the variability within and between patients is kept. An advantage 
compared to STS is that the nonlinear mixed-effect modeling finds the best set of 
parameters and one can perform formal testing of covariates. However, the method is 
slower to run and more advanced to implement compared to STS. [2, 4, 10, 11, 15, 
16] 
NOMEM was the first true nonlinear mixed-effect modeling program and is currently 
the most used program in the pharmaceutical industry for this purpose. 
2.2 NONMEM 
2.2.1 Background 
Shreiner et al. suggested as early as the 1970’s to use nonlinear mixed-effect 
regression models to quantify inter- and intra-individual variability. The concept 
further developed into a computer program, NONMEM, which was released in the 
early 1980’s by Lewis Shreiner and Stuart Beal. [2] 
NONMEM is a computer program written in FORTRAN77, used together with two 
programs, PRED for population pharmacokinetics (PREDPP) and NONMEM 
translator (NM-TRAN). Besides being the oldest, NONMEM is probably the most 
widely used population analyze program today. NONMEM is validated and a well 
accepted program for PK/PD analysis and allows large flexibility in the building of 
models as well as in the data input.  
NONMEM was the first modeling program designed to analyze large amounts of PK 
data using nonlinear mixed-effect modeling.  
In the NONMEM program, linearization of the model in the random effects is 
effected by using the first-order (FO) Taylor series expansion with respect to the 
random effect variables ηi and εij. NONMEM implements two alternative estimation 
methods; the Laplacian method which uses second-order expansions about 
conditional estimates of random effects, and the first-order conditional estimation 
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(FOCE) which uses Taylor series expansion method. FOCE uses an expansion about 
conditional estimates (empirical Bayesian estimates) of the inter-individual random 
effects rather than about zero. [17, 18]  
FOCE is the most widely used approach in PPK, and is also applied in this thesis.  
2.2.2 Modelling population PK using NONMEM 
NONMEM requires two specific files for modelling. Both are created by the user and 
they are called the input- and control file. The input file is where the data are stored. 
They are often arranged as follows: the first column is the patient ID e.g. 1, 2, 3 etc, 
and in the next correlating columns are other PK data such as when the drug was 
delivered (time), drug amount given, concentrations measured etc. This is also where 
information about other variables (covariates) that might be relevant are included, for 
example creatinine clearance, weight, height, sex etc. [7] 
The other file used by NONMEM is the control file. This file describes the structural 
model and states what NONMEM shall do with the input data. If it is to believe that 
the model has one or several compartments, zero, first or multiple order absorption or 
elimination etc. It contains the model and parameter specifications. [7] 
Population modeling with NONMEM means that besides describing the PK 
parameters for the population, inter-individual and residual variability also needs to 
be described. The inter-individual variability () in the PK-parameters i is described 
exponentially shown in equation 1 where  is the individual j pharmacokinetic 
parameter. 
Equation 1:  Pij = j * exp(ij) 
Residual variability can be described by a number of different models: additive 
models, proportional (CCV; Constant Coefficient of Variation) models, exponential 
models, power function model, and combined additive and proportional model 
(slope-intercept model).  
The additive error model is described with the following equation: 
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Equation 2: 1ˆ YY  
The proportional error model is described with the following equation: 
Equation 3:  11ˆ YY  
The combined model describes the residual variability with the following equation: 
Equation 4:   211ˆ  YY  
Where Yˆ  is the predicted concentration, and the randomly distributed terms 1  and 
2  have zero mean and variances 1  and 2 . 
Testing for covariates can be carried out using several methods. [7] Covariates are 
often divided into two groups; continuous- (weight, creatinine clearance, height, age 
etc.) and categorical variables (gender, diabetes, CYP-genotype etc.). 
In this thesis the following methods were used: proportional, linear, power function, 
mean-centered model and if/else model: 
Equation 5: Linear model: valueariatevcoTV ppop  1  
Equation 6: Proportional model: valueariatevcoTV ppop  /  
Equation 7: Power function: valueariatevcoTV ppop  /
2
1  
Equation 8: Mean centered model: 
 valueariatevcomeanvalueariatevcoTV ppop  1  
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Equation 9: IF/ELSE model: 
 IF (OBSERVATION.EQ.X) THEN 
TVpop = p + 1 
ELSE 
TVpop = p + 2 
ENDIF 
2.2.3 How to find the best model using maximum likelihood 
approach 
Parameter estimation in a model is often done with the maximum likelihood approach 
by minimizing the -2log likelihood (-2LL)-function:  
Equation 10:    








 

n
i i
ii
i
YY
nL
1
2
2
2
ˆ
log)2log()log(2

  
Where Y is the measured observation, Yˆ  is the prediction of that observation by the 
model, and 2  is the variance of the model. The second part of the equation: 
   








 

n
i i
ii
i
YY
1
2
2
2
ˆ
log

  is sometimes called the “extended least squares” objective 
function, and from this equation the objective function value (OFV) can be obtained. 
To maximize the likelihood -2LL has to be minimized. Since the first part nlog(2π) is 
a constant focus has to be set on the last part of the equation.  
The likelihood ratio test is a common test for statistical significance. It allows a 
possibility to compare two models that are nested with each other and one can test the 
significance of the parameter which differs between the two models. The difference 
between -2LL values follows a chi-square distribution, with the degrees of freedom 
being the difference in the number of parameters. With a probability of 0.05 and 1 
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degree of freedom the value of the chi-distribution is 3.84. Accordingly, if the 
difference in -2LL values (OFV) for two models that differ with 1 parameter exceeds 
3.84, then the parameter is significant at p<0.05. [7] 
It is important to remember that the model with the lowest OFV is not necessarily the 
best model. OFV differs from model to model and a comparison can not be justified 
when more than one/two parameters are changed at a time. Depending on the purpose 
of the model, several factors should be involved in deciding which model is better; 
run-time vs. visual plots vs. OFV etc.
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3. CYCLOSPORIN A 
3.1 History 
Cyclosporin A is a small hydrophobic cyclic polypeptide of 11 amino acids, among 
them a characteristic unsaturated C-9 amino acid, with a molecular weight of 1202.6 
dalton. CsA was first discovered through screening of lower fungus extracts. Active 
metabolites from the fungus Cylindrocarpon lucidum showed both mild antifungal 
activity and antibody depression in mice. [19, 20] 
Oral administration in mice and rats showed a strong depression of the appearance of 
both direct and indirect plaque-forming cells and produced an obvious dose-
dependent, yet reversible inhibition of haemagglutinin. Skin graft rejection in mice 
and graf-versus-host disease in mice and rats was considerably delayed by CsA. Soil 
samples collected in Norway in March of 1970 showed that the fungus 
Tolypocladium inflatum also contained CsA. This fungus was originally classified as 
Trichoderma polysporurn. In 1972 CsA proved to have powerful immunosuppressive 
properties. Since then much research has been performed on this drug. [19, 21]  
3.2 Application and mechanism of action 
Cyclosporin A was introduced to the market in the early 1980’s and has since then 
been a cornerstone of solid organ transplant procedures. CsA led to for example an 
improvement in transplant kidney graft outcome, and made it possible to transplant 
hearts. [22-24] It has played a major part in the success of immunosuppression in the 
clinical setting since its introduction. [24] 
CsA acts by forming a complex with the intracellular protein cyclophilin A, a protein 
localized in the cytoplasm of lymphocytes. This complex binds to and inhibits 
calcineurin that will ultimately lead to interference with activation of T-cells and 
production of interleukin-2. [20, 25-28] 
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CsA gives a better response to infection compared to other immunosuppressive 
agents because it suppresses T-cells partially, while it to some extent spares B-
lymphocyte activity. [25, 26, 28] 
3.3 Known problems with Cyclosporin A 
When administrating immunosuppressive agents to patients it is important to obtain 
an optimal exposure of the drug.  The most important reason for this is to prevent 
acute rejection, which secondarily will prolong the survival of the grafts and 
ultimately, the patients. Since CsA has a narrow therapeutic window it is challenging 
to keep the concentration levels within the therapeutic window. 
Besides having a narrow therapeutic window CsA has a large inter-individual 
variability. This is especially visible after oral administration where observations 
show great variability. Below the therapeutic window there is a high risk of acute 
rejection, while concentrations above the therapeutic window are associated with 
minor and severe side effects such as anorexia, gastrointestinal disturbances, 
nephrotoxicity, infection, hepatotoxicity, dyslipidemia, hypertension and 
development of diabetes and cancer. [29-31] 
There are also a wide range of drugs and other agents that interact with CsA 
pharmacokinetic which can cause a decrease or increase in concentration levels. All 
of these factors make it important to make a representative PPK-model to obtain an 
optimal treatment. [25, 26] 
3.4 ADME OF CsA 
3.4.1 Administration 
CsA exists in two administration forms, infusion or orally. Oral administration can 
further be divided into capsules and mixture. [32] 
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The plasma peak concentration is obtained after 1-2 hours. The absorption profile is 
often characterized by a lag phase followed by rapid absorption. The site of 
absorption is predominately in the small intestine and due to its lipophility the 
absorption is dependent of bile flow, gut motility, food and time after transplantation. 
[33, 34] 
Bioavailability of CsA normally ranges from 30-60 %. [32] 
3.4.2 Distribution 
Because CsA is highly lipophilic the distribution will to a large degree bind outside 
the blood circulation. Within whole blood CsA will distribute highly to erythrocytes 
41-58%, plasma proteins 33-47%, granulocytes 5-12% lymphocytes 4-9%. In plasma 
approximately 90% is bound to plasma proteins, mainly lipo proteins. [32] 
3.4.3 Metabolism 
CsA has an extensive metabolism. It is metabolized in liver, small intestine and 
kidney to approximately 30 metabolites. The reactions involved in phase 1 
metabolism are oxidation, hydroxylation and demethylation. [35, 36] 
Cytochrome P450 system, in particular CYP3A4 and CYP3A5 are responsible for the 
Phase 1 biotransformation. CsA is also a substrate and inhibitor for the ATP-binding 
cassette transporter protein, P-glycoprotein (P-gp, mdr-1/ABCB1). [37, 38] CYP-
enzymes and P-gp work together in hindering CsA to access the systemic blood 
circulation. Since both systems are present in a large degree in both intestines and 
liver CsA is subject to a large first pass metabolism and accordingly shows a low oral 
bioavailability. 
Patients with geno typical differences in CYP3A protein expression will therefore 
have large variations in CsA PK. [35, 38-40] 
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3.4.4 Elimination 
CsA is mainly eliminated through the biliary system. 6% of the oral dose is 
eliminated renally while less than 1% excretes unchanged through the urine. [32] 
Depending on the population and method used, half life varies to a great extent. Half 
life varies from 6 hours for healthy volunteers to 20 hours for patients with severe 
liver complications. [32] 
3.5 Therapeutic drug monitoring 
Due to the complex reasons for variability of CsA it is subject for therapeutic drug 
monitoring (TDM) to maximize the effect of the immunosuppressive therapy.  
The parameter most closely linked to the therapeutic effect and the toxic effect is 
thought to be the area under the whole blood versus time curve from 0 to 12 hours 
(AUC0-12). This way of measuring drug exposure is both time consuming and 
expensive and is rarely done. An often used method is measuring concentrations at 
trough level (C0), and/or 2 hours after dosing (C2) which is considered a better marker 
for toxic effects. [41, 42] 
Studies have shown that there are valid arguments for monitoring intra-lymphocytic 
CsA trough levels (C0-intracellular). Since CsA’s effect is initiated by its binding to its 
lymphocyte receptor, a measurement here would be “at the site of action” and a more 
advantageous way to monitor. [29, 30, 43, 44] 
The super CsA-study showed that by measuring the intracellular concentration, one 
may potential to detect acute rejection several days earlier than possible with 
traditional methods, [45] making it an attractive option to monitor CsA-
concentrations inside the T-lymphocytes as well as in whole blood concentrations. 
The intracellular concentration appears to provide information about processes 
important to rejection which whole blood concentrations do not provide. CsA whole 
blood concentrations actually tend to be slightly higher for the rejection patients 
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during that study and did not correlate with the intracellular concentrations that were 
declining days before rejection. [45] 
Developing a successful PPK-model for CsA can prove useful. General dosing 
regiments today is based on the physicians experience and knowledge. With a PPK-
model it will hopefully be possible to give more correct doses to each individual at an 
earlier time. 
3.6 Population kinetic models of CsA in literature 
Through the history there have been many attempts to model the PK of CsA. 
Different attempts have resulted in different conclusions. Both 1- and 2- and 3-
compartments have been used and different Erlang distribution and absorption lag-
time have given a good fit. This also applies to covariates where a wide range has 
been found significant. [38, 46-51] 
3.7 Goals of the thesis 
The objective of this thesis is to include a T-lymphocyte compartment to the whole 
blood model and continue develop the previous CsA model made by Truc van Le 
[48] and Live Storhagen [49] by including 20 more patients, followed for at least 8 
weeks, re-evaluate for covariates and test the model for interoccasional variation 
which has not yet been tested. 
 
METHODS AND MATERIALS 
 27 
4. METHODS AND MATERIALS 
4.1 Materials for the whole blood model 
The whole blood model consists of totally 70 patients from 4 different studies. [45, 
52-54] 
There are differences in the amount of information gathered from each study. The 
medical records included information about date, time, CsA dosage, CsA 
concentration, gender, weight, serum creatinine, urea, current co-medication and 
transplantation date. A full PK population design was used to allow blood samples to 
be drawn at different times. [5] A total number of 1276 measured drug concentrations 
were used in the model development. 
All patients received renal transplantation at Rikshospitalet University hospital HF, 
Oslo, Norway. CsA (Sandimmun Neoral®, Novartis Pharmaceuticals Corporation, 
Switzerland) was administered orally twice daily in soft gelatin capsule formulation, 
along side other routine protocol medication. 
Patients 1-5, 8-11, 16-18, 20-22, 24-25, 31, 34 and 38 were from the POPDOC study. 
[54] 
Patient 101-120 were from the super-CsA study. [45] This was a single prospective 
pilot study following patients from 0-17 weeks after transplantation, with 
measurements made sporadically at trough level C0 and C2 (2 hours after CsA 
administration). Nine of these 20 patients had a 12-hours pharmacokinetic profile 
done once in this period. [45] 
Patient 130-137 originated from the MIMPARA-study [53] which was an interaction 
study between Cinacalcet and immunosuppressive drugs. Only CsA data from before 
Cinacalcet was administrated was used in this model. [53] 
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The remaining 21 patients (151-165, 167-172) were from a CsA study performed to 
screen for possible age effect on PK of CsA. [52] 
Whole blood samples drawn specifically for the clinical trials were analyzed for CsA 
concentrations using a validated LC-MS/MS method [55], while routine clinical 
follow up samples were analyzed using Cedia Cyclosporine PLUS Assay (CEDIA+) 
(Cloned Enzyme Donor ImmunoAssay; Microgenetic Corporation, Fremont, CA) 
method at the clinical chemistry department at Rikshospitalet. All blood 
concentrations used in the development of the model were transformed to CEDIA+ 
equivalent concentrations. [55] 
Whole blood samples for the 12-hours PK-profiling were analyzed at both the study 
center, Rikshospitalet University Hospital HF and by the Department of 
Pharmaceutical Biosciences, University in Oslo, while whole blood samples taken 
sporadically were analyzed by Rikshospitalet University Hospital HF. Analysis 
results showed that there was significant inter-laboratory variability. This may be the 
result of the different analysis methods. All CsA concentrations analyzed by the 
Department of Pharmaceutical Biosciences were therefore adjusted to the correct 
concentration, as defined by Rikshospitalet University Hospital HF, with the 
following equation: 
Equation 11: RH=DPB × 0.88 
Where RH is the adjusted concentration according to Rikshospitalet University 
Hospital HF, and DPB is the concentration obtained from analysis performed by the 
Department of Pharmaceutical Biosciences. This equation was obtained from 
correlation of concentrations measured at both laboratories in the three studies. [48] 
As data was gathered at various times, it was no missing data points so to speak. In 
the NONMEM input file C0 levels was computed for morning doses at 06.00 hours 
and at 20.00 hours for evening doses while C2 levels was coded at 08.00 hours and at 
22.00 hours for evening doses. 
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Table 1. Patient demographics whole blood 
    Range 
Number of patients 70   
Number of male/female patients 47/23     
Age (years) 56.4 21-78.6 
Weight (kg) 79.7 49-124 
Height (m) 1.77 1.53-1.92 
Body mass index (kg/m
2
) *
1
 25.3 16.7-34.3 
Lean body mass (kg) **
2
 53.8 75.6 
Gender male 47   
Gender female 23   
CYP 3A5 genotype;     
*1/*3 9   
*3/*3 61   
Time after transplantation (weeks) 5.6 1.0-17.0 
Estimated creatinine clearance (ml/min) ***
3
 70.8 18.3-162.5 
Cyclosporine A     
Observed whole blood concentrations (ng/mL) 937.1 30-3240 
Total number of samples 1276   
Average number of samples per patients 18   
*1
 Estimated using BMI-formula, **
2 
estimated using LBM-formula, ***
3
estimated using Cockgroft-
Gault equation (Formulas found in Appendix 9.1) 
4.2 Materials for the whole blood model and intracellular 
concentrations 
Data for the combined whole blood and intracellular concentration was based on the 
patients from the super-CsA study. [45] From the same patients 20 patients there was 
also obtained intracellular concentrations. From these 20 patients, nine patients had a 
12-hour PK-profile done once in the study period. 
The intracellular samples were measured in T-lymphocytes. T-lymphocytes were 
isolated from 7 ml whole blood using Prepacyte (BioE, St. Paul, MN). CsA 
concentrations were measured in freshly isolated T-lymphocytes using a validated 
liquid chromatography (LC) double mass spectrometry (MS/MS) method. The 
intracellular levels of CsA were then related to the number of T-lymphocytes (ng/10
6
 
cells). [45] 
METHODS AND MATERIALS 
 30 
The data was computed similar to the whole blood model where C0-levels was coded 
at 06.00 hours for morning doses, and at 20.00 hours for evening doses, while C2-
doses was coded at 08.00 hours for morning doses and at 22.00 hours for evening 
doses. 
Table 2. Patient demographics whole blood and intracellular model 
    Range 
Number of patients 20   
Number of male/female patients 13/7     
Age (years) 53.6 21-74 
Weight (kg) 77.9 58.5-100.5 
Height (m) 1.78 1.65-1.88 
Body mass index (kg/m
2
) *
1
 24.7 19.3-32.9 
Lean body mass (kg) **
2
 55.5 46.3-66.6 
Gender male 13   
Gender female 7   
CYP 3A5 genotype;     
*1/*3 2   
*3/*3 18   
Time after transplantation (weeks) 6 1.0-17.0 
Estimated creatinine clearance (ml/min) ***
3
 76 18.3-162.5 
Cyclosporine A     
Observed whole blood concentrations LN (ng/mL) 6.76 3.4-8.1 
Observed intracellular concentrations LN (ng/mL) 10 6.5-13.6 
Total number of whole blood samples 510   
Total number of intracellular samples 420   
Average number of samples per patients 52   
*1
 Estimated using BMI-formula, **
2
estimated using LBM-formula, ***
3
estimated using Cockgroft-
Gault equation. (Formulas found in Appendix 9.1) 
4.3 Developing and building the models 
All computations were done using NONMEM (version VI; GloboMax LLC, 
Hanover, MD, USA). Graphical diagnostics plots were obtained from the program R 
(http://www.r-project.org) and in some situations drawn using Microsoft® Office 
Excel 2003 (USA) and Minitab® Statistical Software version 15.1.20.0 (State 
College, Pennsylvania, USA). 
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4.3.1 The whole blood model 
For the whole blood model, there was no model development process. The model had 
already been developed and undergoing clinical testing in the POPDOC-study when 
this thesis was begun. The model was tested and validated to being a 2-compartment 
model with lagtime. Significant covariates had already been identified, but these were 
now re-validated with more patients using forward inclusion and backwards deletion 
process. 
Testing for interoccasional variability required a new column to be added to the data 
set. This column identifies the different visits each patient had when samples were 
taken. IOV was later coded in the control file by using the separate visits to equal 
different etas. The BLOCK(1) option was also included. (Appendix 9.3) 
It was made several attempts of modeling IOV into the model. The first attempt was 
made by marking each date with a measured sample as different visits and tested on 
one parameter at the time. The number of visits ranged from 22-46 for the different 
patients.  
NONMEM had problems with too many etas and NM-TRAN gave an error statement 
when too many visits were tried estimated, accordingly it was only possible to code 
the first 11 visits. 
To avoid this problem every second dates (with measurements) was marked as a 
different visit. For example, the first two dates with samples were marked “visit 1” 
and the third and fourth samples marked “visit 2” and so on. This was done to keep 
the time perspective of the samples. IOV was then tested at one parameter at the time. 
4.3.2 The whole blood and intracellular model 
Developing a model with both whole blood and intracellular concentrations was a 
time consuming and demanding task. 
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The first process step was to include the intracellular concentrations to the data set 
including the whole blood. Then the different concentrations had to be separated 
using dependent variable identification (DVID). The data are divided by 
EVID/DVID, where DVID = 1 is whole blood concentrations, DVID = 2 is 
intracellular concentrations. EVID = 0 is no observation, EVID = 1 is whole blood 
observation and EVID = 2 is intracellular observations. Corresponding IPRED = 1 is 
whole blood individual prediction and IPRED = 2 is individual intracellular 
concentration predictions. 
Building on the previous model the idea was to add another compartment which was 
the intracellular compartment (Figure 2). Clearance (CL) and volume (V) was 
parameterized and inter-compartmental rate constants were estimated by CL and V. 
(Appendix 9.6) 
A $DES code was added to the control file to describe the absorption and elimination 
profiles for the different compartments. Previous studies on the same subjects 
indicated that the absorption process in the intracellular compartment was following a 
1.order reaction. 
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Figure 2: Compartment theory for the model including whole blood and intracellular concentrations. 
A 4-compartment model where the drug absorbs from the absorption compartment (1) into the central 
compartment (2) and from there, it is distributed into the peripheral compartment (4) and eliminated. 
The intracellular concentrations are represented in the intracellular compartment (3) where there is 
equilibrium with the central compartment (2). 
 
The whole blood concentrations were measured in ng/ml while the intracellular 
concentrations were measured in ng/10
6
 cells.  
In an attempt to convert the intracellular concentrations to the same unit, an estimate 
of a T-cell volume had to be made. The T-cell’s diameter was estimated to 8*10-6 m 
in diameter and the volume was estimated to have a spherical shape. 
Diameter: 8 μm 
Equation 11: Volume = (4/3) * π * r3 
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Similar approaches were tested to the converted concentrations without significant 
luck. There were signs that NONMEM was able to predict that the observations was 
independent, but because of the very large concentration differences (intracellular ≈ 
80000ng/ml vs. whole blood ≈ 3000ng/ml) NONMEM was not capable of reaching 
concentrations that were high enough. 
As a result of this the data were LN-transformed and a necessary new residual error-
code was included in the model. It was checked against both only proportional error 
and additive error, and the combined proportional and additive error. 
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5. RESULTS 
5.1 Re-analyzing for covariates for the whole blood model 
The fixed effects parameters estimated for the final 2-compartment model were CL/F 
(Θ1), V1/F (Θ2), Q/F (Θ3), V2/F (Θ4), Ka (Θ5), and ALAG (Θ6).  
In the screening process all covariates (table 3) were tested individually on each 
parameter. All the positive covariates were then double checked for significance in 
the second screening (table 4). All the covariates found significant were further 
included in the model (table 4) before the backwards deletion process (table 5). 
Table 3. Covariates tested 
Lean body mass (LBM) CYP P450 3A5 (3A5) Steroid dose (STER) 
Body mass index (BMI) Height (HGT) Gender 
Post transplantation TXT) Age (AGE) Diabetes 
Creatinine Clearance (CRCL) Weight (WT)   
 
Table 4. Covariates found significant during forward inclusion for the whole blood 
model 
Parameter Covariate Model OFV ΔOFV P 
CL/F CRCL Θ1-Θ7*CRCL 14723.41 -10.7 >0.01 
  LBM Θ1-Θ7*(LBM-53.8) 14702.31 -31.8 >0.01 
  
C3A5 IF (C3A5.EQ.1) THEN Θ1*Θ7 
ELSE Θ1*Θ8 ENDIF 14722.24 -11.9 >0.01 
  BMI Θ1-Θ7*BMI 14724.21 -9.88 >0.01 
  AGE Θ1-Θ7*AGE/56 14722.79 -11.3 >0.01 
V1/F AGE Θ2/Θ7*AGE 14712.37 -21.7 >0.01 
  TXT Θ2*Θ7*(TXT/5) 14702.99 -31.1 >0.01 
  BMI Θ2*Θ7*BMI 14699.29 -34.8 >0.01 
Q AGE Θ3-Θ7*AGE 14721.85 -12.2 >0.01 
  WT Θ3*Θ7*WT 14710.95 -23.1 >0.01 
  CRCL Θ3+Θ7*CRCL 14709.53 -24.6 >0.01 
  STER Θ3-Θ7*(1+STER/100) 14718.7 -15.4 >0.01 
V2 AGE Θ4+Θ7*(AGE-56) 14719.72 -14.4 >0.01 
  CRCL Θ4-Θ7*CRCL 14721.24 -12.9 >0.01 
  LBM Θ4+Θ7*(LBM-53.8) 14723.34 -10.8 >0.01 
  STER Θ4-Θ7*(1+STER/100) 14729.07 -5.02 >0.01 
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Ka AGE Θ5-Θ7*AGE 14710.01 -24.1 >0.01 
  CRCL Θ5*Θ7*CRCL 14711.12 -23 >0.01 
  STER Θ5-Θ7*(1+STER/100) 14724.99 -9.1 >0.01 
  BMI Θ5-Θ7*BMI 14700.16 -33.9 >0.01 
  WT Θ5-Θ7*(WT-78.5) 14717.26 -16.8 >0.01 
  TXT Θ5*Θ7**TXT/5 14686.4 -42.8 >0.01 
ALAG AGE Θ6+Θ7*AGE 14719.06 -15 >0.01 
 
From the early screening process many of the same covariates were found as 
expected.  
When all covariates from the forward-inclusion were added the OFV was 14597.34. 
After the backwards deletion step, the following covariates were left in the model 
(table 5). 
Table 5. Covariates found significant after backwards deletion for whole blood model 
Parameter Covariate Model OFV ΔOFV P 
CL CRCL Θ1-Θ7*CRCL 14642.19 44.85 >0.01 
  
C3A5 IF (C3A5.EQ.1) THEN 
Θ1*Θ7 ELSE Θ1*Θ8 ENDIF 14852.22 254.88 >0.01 
  AGE Θ1-Θ7*AGE/56 14614.15 16.81 >0.01 
V1/F AGE Θ2/Θ7*AGE 14712.37 14.97 >0.01 
  BMI Θ2*Θ7*BMI NA NA NA 
Q WT Θ3*Θ7*WT 14710.95 18.24 >0.01 
  STER Θ3-Θ7*(1+STER/100) NA NA NA 
Ka TXT/5 Θ5*Θ7*TXT**5 14624.7 27.36 >0.01 
  BMI Θ5-Θ7*BMI NA NA NA 
  AGE Θ5+Θ7*AGE NA NA NA 
 
OFV in the start model was 14734.09 and dropped to 14597.34 when all the 
significant covariates were added. After the backwards deletion the final model had 
an OFV of 14643.28 which is a significant improvement. 
When comparing the final model to the first model several similarities of significant 
covariates were found. Both Truc’s model and the model used in the POPDOC-study 
found these covariates to be significant in their models. 
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5.2 Testing for interoccacional variability 
By looking at the data there is reason to suspect interoccasional variability (IOV). 
After the alteration of visits (every other visits where coded as different visits) there 
was a change in OFV for V2. 
Table 6. OFV change after inclusion of interoccacional variability 
on the different parameters 
  OFV ΔOFV 
CL 14696.27 52.99 
V1 14665.4 22.12 
Q 14687.8 44.52 
V2 14612.72 -30.56 
Ka 14723.22 79.94 
ALAG NA NA 
 
Inclusion of OFV on the parameter V2 gave a significant reduction of OFV. 
Remembering the OFV with covariates to be 14643.28, there was an OFV-change of 
30.56 which makes the model with IOV significant better than the model with 
covariates and the model without covariates. 
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5.3 Covariate analysis based on visual prediction 
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Figure 3. Scatterplot for whole blood model without covariates - IPRED versus Concentration 
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Figure 4. Scatterplot for whole blood model with significant covariates - IPRED versus 
Concentration 
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Figure 5. Scatterplot for whole blood model with significant covariates and interoccasional 
variability - IPRED versus Concentration 
The first three scatterplots (figure 3-5) show the development from the model without 
covariates to the inclusion of significant covariates and finally with significant 
covariates and interoccasional variability. There is a gradually improvement as seen 
earlier by the decrease of OFV. The increasing R
2
 together with the decrease of S 
show that there is a better fit and the regression line shows an improving description 
of the data. 
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Figure 6. Whole blood model with significant covariates and IOV. Scatterplot of Wres vs. time. 
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Figure 7. Whole blood model with significant covariates and IOV. Scatterplot of Wres vs. ID. 
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Figure 8. Whole blood model with covariates and IOV. Scatterplot Wres vs. ipred. 
Figure 6-8 shows the final model with significant covariates and IOV, WRES versus 
time, ID and population prediction (PRED). The weighted residuals (WRES) are 
evenly distributed with time and identification (ID). WRES versus population 
prediction (PRED) shows that the weighted residuals are tending towards the 
negative side for the large concentration predictions implying that there is a small 
over-prediction for the large concentrations. 
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Figure 9. Quality of fit plot, whole blood model with all significant covariates and IOV 
 
Figure 10. Goodness of fit, whole blood model with all covariates and IOV 
The remaining figures (9-10) are parts of the diagnostics plots drawn by R-script of 
the final model. The figures show that POSTHOC gives an overall good prediction 
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for the final model. It also shows that NONMEM has small problems fitting the 
concentrations on the highest and lowest end of the scale. Overall there is a good 
prediction with an even spread around the regression line. 
5.5 Comparing the old versus the new model 
Table 7. Comparison of significant covariates from old model versus new model 
Previous covariates* Current covariates 
Parameter Covariates Parameter Covariates 
CL Age CL Age 
    CRCL 
    Cyp3A5 
V1 
Age 
V1 
Age 
Weight BMI 
KA 
TXT 
KA 
TXT 
Age Age 
Weight BMI 
   Q Weight 
      Steroid dose 
*The last version of the model, the model used in the POPDOC-study. 
Comparing the new model with the old model shows several similarities. Both 
models are pretty accurate for the low to normal levels of CsA, but have some 
difficulties predicting concentrations on the higher level of the scale. The covariates 
found significant are majorly the same (table 7). Furthermore the scatter-plot of 
weighted residuals are evenly distributed which is acceptable. The new model has 
IOV included, which is expected, and this factor may be decisive of small, but 
significant improvement of the model.  
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5.6 The whole blood and intracellular concentrations 
5.6.1 Model building results 
The data were LN-transformed and the necessary new error code was included in the 
model. Using a proportional and an additive error code for the inter-individual 
variability gave the best fit and lowest OFV.  
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Figure 11. Patient 7, concentration vs. time. LNDV = 1 for whole blood concentrations, LNDV = 2 
for intracellular concentrations and the corresponding IPRED = 1 for individual whole blood 
predictions and IPRED = 2 for individual intracellular predictions. The y-scale (concentrations) is 
presented on LN-scale while the x-scale is time (h). The time units are not homogenous, but rather 
time measured when the different samples were taken. The graph is showing C0, C2 and 12-hours 
profile data. The marked area represents the 12-hour profiles and enlarged in the figure below is the 
12-hours profile for the same patient 
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Figure 12. Patient 7 – 12-hours PK-profile. For detailed description see Figure 11 
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Figure 13. Patient 10 – concentrations vs. time. For detailed description see Figure 11 
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Figure 14. Patient 10 – 12-hours PK profile. For detailed description see Figure 11 
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Figure 15. Patient 19 – concentrations vs. time. For detailed description see Figure 11. 
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Figure 16. Patient 19 – 12-hours PK profile. For detailed description see Figure 11. 
According to the graphical comparisons the whole blood and intracellular model is 
able to tell the difference between the different observations. It seems as if it predicts 
C2-levels better the trough concentrations. The model is to some degree able to 
predict the large fluctuations of the observed concentrations. (Figure 11, 13 and 15) 
The 12-hours profile is however rather inaccurate. (Figure 12, 14 and 16)  
The absorption phase is wrongly estimated both for the whole blood and the 
intracellular concentrations (Figure 12, 14, 16-19). The elimination phase is a little 
over-predicted for the whole blood concentrations, and it does not match the 
intracellular concentrations too well either. 
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Figure 17. Mean intracellular 12-hours profile, 12-hour profile for the mean observed and predicted 
intracellular concentrations shown on a normal-scale versus a normal time-scale (h). The SEM-
interval is represented at each measurement. 
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Figure 18. Mean whole blood concentrations 12-hours profile. 12-hour profile for the mean observed 
and predicted whole blood concentrations shown on a normal-scale versus a normal time-scale (h). 
The variations on the predicted concentrations are represented by the SEM-interval. 
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Figure 19. Mean whole blood concentrations 12-hours, DVID = 1 = Whole blood. 12-hour profile for 
the mean observed and predicted whole blood concentrations shown on a reduced normal-scale 
versus a normal time-scale (h). The variations on the observed concentrations are represented by the 
SEM-interval. 
Figure 17-19 are mean whole blood- and intracellular 12-hours PK profiles for the 9 
patients. The figures confirm the earlier findings that the absorption phase is wrongly 
estimated for both whole blood and intracellular measurements. The absorption phase 
for whole blood predictions is too fast with a lower Tmax and a very increased Cmax, 
but the elimination phase for the predicted is in the same ballpark-area as the 
observed. For the intracellular 12-hours PK the absorption phase is very similar for 
both the predicted and observed concentrations, with the predicted Cmax a little lower 
than the observed and the Tmax a little earlier. The elimination phase is unfortunately 
not similar for the predicted and observed concentrations.  
The standard error of the mean (SEM) is represented as the interval for both the 
observed (SEM = 3448.31) and the predicted concentrations (SEM = 2543.99) for 
intracellular concentrations (figure 17). Regarding the whole blood measurements 
SEMpredicted is very large (SEM = 11749.34) because of Cmax. Therefore SEM for 
predicted whole blood concentrations are presented in figure 18 with a full Y-scale, 
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while SEM for the observed concentrations (SEM = 132.14) are presented in figure 
19 with a reduced Y-scale. 
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Figure 20. Scatterplot of LNDV vs. IPRED. DVID = 1 is whole blood predictions, DVID = 2 is 
intracellular predictions. 
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Figure 21. Scatterplot of WRES vs. time. DVID = 1 is whole blood predictions, DVID = 2 is 
intracellular predictions. 
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Figure 22. Scatterplot of WRES vs. ID. DVID = 1 is whole blood predictions, DVID = 2 is 
intracellular predictions. 
 
The scatterplot of LNDV versus IPRED (Figure 20) shows that the predictions are 
still rather inaccurate. Figure 21 shows that the weighted residuals are stable over a 
period of time, but the scatterplot of WRES versus ID (figure 22) shows for all 
patients that the weighted residuals are negative for whole blood concentrations 
which give an indication that the predictions are over-predicted.
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6. DISCUSSIONS 
6.1 Re-analyzing for covariates for CsA 
plasmaconcentrations 
As expected there were many covariates influencing different PK-parameters. During 
forward inclusion several covariates showed statistical significant, but most proved 
not to be significant after the backwards deletion process.  
During backwards deletion (table 5) the model would not run without some 
covariates. Due to the recommendation that only one or two parameters should be 
changed in order to compare with the previous OFV, those covariates were kept and 
marked “not applicable” (NA).  [7] 
Storehagen [49] and Le [48] used some of the same data for their thesis and it was 
expected to find similar significant covariates. The covariate screening for their 
theses included: age (years), gender (FLAG = 1 male, FLAG 2 = female), diabetes 
(FLAG = 1 diabetic, FLAG 2 = non-diabetic), weight (kilos), height (centimeters), 
post-transplantation (weeks), steroid dose at the pharmacokinetic day (mg), CYP3A5-
enzyme genotype (*1/x vs. *3/*3) and estimated creatinine clearance (ml/min). 
The surgery performed in renal transplantation patients will most likely affect the 
intestinal motility and hence absorption and bioavailability of CsA in the early post-
transplant phase. Therefore the post-transplantation time will presumably influence 
the absorption constant Ka which also is found. 
Patients gain up to 10% more bodyweight after transplantation and it is not surprising 
that parameters like weight, lean-body-mass and body-mass-index can influence PK-
parameters like Ka, Q and distribution volume. After transplantation, patients are less 
catabolic and they are able to eat more which might increase the body-fat. This is 
supported by the findings of weight and weight-related (BMI) covariates influence on 
Ka, Q and distribution volume. 
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Storehagen [49], Le [48], Falck [56] and Wu [57] have shown earlier that age has a 
significant covariate for CL/F. With increasing age pharmacological changes such as 
loss of liver-mass and the blood flow to liver is reduced, which influences the 
metabolism and clearance of CsA. Physiological changes can also explain the 
significance of age on parameters like volume and absorption. These factors 
strengthen the findings in this thesis that age has a real effect on CL, V1 and Ka. 
Cyclosporin A is metabolized by the cytochrom P450-system as mentioned earlier. 
CYP 3A5 genotypes will most likely affect the clearance of CsA. In earlier studies 
Storehagen [49] did not test this covariate because of various reasons, Le found this 
covariate to be significant in a later study, but it was not included in the final model 
because of clinical relevance.[48] It is therefore no surprise that this was shown to be 
a significant covariate on clearance in this present version of the model.  
Diabetes was tested and found non-significant in this thesis. It has been shown in 
literature that diabetes may affect the absorption rate of CsA. [58] One reason why it 
was not found significant in the present model may be due to the lack of detailed 
description of diabetes in patients. It was only marked as FLAG = 1 diabetes and 
FLAG = 2 non-diabetes. Some patients had diabetes before undergoing 
transplantation and some patients developed diabetes after transplantation thus a more 
detailed coding could have given a different result. This should be tested in the future 
development of the model. 
The covariates found to be statistical significant were mostly the same as previously 
discovered by Storehagen, Le and Falck (table 7). This further supports the theory 
that those covariates are statistical significant for this drug and drug model. 
Overall the OFV decreased significantly during the development of the model, which 
gives a strong indication that the inclusion of covariates improves the model. 
However, the graphs showing concentration vs. individual predictions do not give an 
unambiguous answer. There might be a slightly better population prediction with the 
inclusion of covariates but this is very difficult to see from the figures. There are 
minor signs indicating that the model with covariates has less spread and that the 
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divergence starts a little later. A more secure way of determining this is by looking at 
the decrease of OFV. Along with the R
2
 value and S-value for the regression line for 
the observation versus predictions (Figure 3-4) shows that there is an improvement of 
the model. 
6.2 Testing for interoccasional variability for the whole 
blood model 
Based on the results from the POPDOC-study there is reason to suspect significant 
inter-occasional variability. [54] Due to many visits per patients the chances 
increased to detect if there is something “unexplainable” that happens between 
different visits. There are patients that have a variation that cannot be explained with 
covariates and intra- and inter-individual variability. This gives a strong indication 
that there is something more that influences patients PK-parameters. 
NONMEM has a limit of etas before there is an error statement from FORTRAN. 
There are ways to avoid this problem, but it requires a degree of competence in 
NONMEM coding that is beyond the scope of this research group. Because of this 
limitation it was only possible to code 11 visits per patients which could be a reason 
why the visits were not shown more significant than when coding each measurement-
date as one separate visit. The maximum number of visits one patient had was 34 
visits, thus that way of coding accounted for roughly 40% of the visits.  
When coding every other date as separate visits there was an improvement (decrease) 
in OFV. There was a decrease of 30.56 when including IOV to the parameter V2 
(table 6), making the model significant better with IOV than without. Another 
advantage of coding every other visit as one visit comparing to coding every visit as 
its own, is that about 65% of the visits are included, and the time perspective is kept. 
Still there are some visits that are not accounted for. A hypothesis is that coding every 
visit as “its own visit” will enhance the model further. Another way to do this is by 
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looking at the data and picking the data where there is suspicion of IOV and code 
only these visits.  
Moreover there are also some covariates that are believed to influence the different 
parameters e.g. diabetes. [58] Including all of these factors may improve the model 
and make it even better than it is today. 
From a graphical inspection it is hard to determine which model gives the best fit. 
Due to a large data set there are too many observations to give an unambiguous 
answer. Still, by looking again at the R
2
- and S-value for the regression line an 
improvement is visible from the starting model without covariates to the model 
including covariates and finally the model including covariates and IOV. Similarly, 
by looking at the OFV the value is decreased by first including covariates and then 
including IOV. 
Another way to determine the best model would be a visual prediction check. [59] 
One way to do this is to program R-script. There also exist different add-on programs 
to NONMEM for example xPose, Wings, PsN, which gives a possibility to draw 
more complex graphs. To do this it is necessary to have to have a stand-alone 
NONMEM installation, which was not available. More detailed graphs would provide 
an even better foundation to determine which model that had the best data fit. 
6.3 Whole blood and intracellular model 
The first step to overcome was to make NONMEM to differ between the whole blood 
observations from the intracellular observations. This was an extremely challenging 
task and was more difficult than first imagined. An unexpected hinder was the run 
time the model had. In the beginning most runs used approximately 1 day. After the 
transformation of intracellular concentrations from ng/10
6
 cells to the same unit 
(ng/ml), as the whole blood concentrations were measured in, there was an enormous 
range from whole blood concentrations to intracellular concentrations. This large 
range made data fitting nearly impossible. Finally after LN transforming the 
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concentrations there were difficulties finding the correct error code to include in the 
model. In the end when the data fittings at last seemed promising, time was running 
out. 
The final model seems capable of predicting the concentrations at two different sites. 
The WRES vs. time/ID shows an overall over-prediction for the intracellular 
concentrations and an under-prediction for the whole blood values. The over-
prediction of whole blood concentration is largely due to the Cmax in the 12-hours PK. 
The difference between predicted value and observed concentration is so high that it 
will affect the mean prediction power. It seems as though the model fits the C2-levels 
slightly better than the C0-concentrations, but it still has trouble fitting the large 
variety of concentrations.  
For the 12-hours whole blood profile it is visible that the model has large problems in 
the absorption phase, which indicates that the Ka is over estimated. The elimination 
however seems to be rather accurate compared to the absorption phase. It is obvious 
that Ka is estimated wrongly when NONMEM predicts it to be 55 on a LN-scale. The 
high Ka is the reason for the high predicted Cmax for whole blood (140000 ng/ml – 
1600 ng/ml – figure 18-19). The high Cmax increases the SEM which makes the 
predictive power worse as mentioned earlier.   
An attempt to force/lock Ka to a lower value resulted in a more correct Cmax for 
whole blood. Cmax went from 140000 ng/ml to 22000 ng/ml compared to 1600 ng/ml, 
but resulted in a more identical whole blood and intracellular prediction with a lack of 
concentration-variety. (Appendix 9.8) The absorption-phase is also delayed with Tmax 
estimated to be approximately 1 hour later than the true value. (Figure 17-19) 
The intracellular 12-hours profile has predictions in the same range as the measured 
observations. The absorption phase is however slightly delayed. The absorption into 
the intracellular compartment is estimated to be a 1.order reaction. This is a 
reasonable assumption by looking at the measured concentrations and considering 
there is a passive diffusion of CsA into T-lymphocytes and not an active transport. It 
could be an idea to test other absorption-profiles to find a more fitting description. 
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The concentrations/LNDV vs. Ipred did not attain the desired degree of consistent 
prediction. (Figure 20) The “inclusion” of the whole blood model has not been 
optimal. One way to possibly improve this model is the inclusion of covariates. 
However, before the covariates are tested the basic model needs to be improved, 
especially the absorption rate constant, and the absorption and elimination processes. 
The model is still in an early stage and needs to be further developed. 
Since the model is still in a development phase it is premature to validate the model. 
After further development with the inclusion of covariates and IOV the model should 
be validated following FDA’s guidelines. [5] The validation process consists of 
external validation (including new patients) or internal (using the existing data set). A 
useful and common validation method for this data set could be cross-validation, 
bootstrapping and Jackknife. 
In a retrospective view it should be possible to develop a model based on the original 
intracellular data. NONMEM does not understand units, meaning it only reads 
numbers. Accordingly it should be possible to develop a model based on the original 
data and unit (ng/10
6
 cells). Doing this has many benefits i.e. there is no need to 
transform data, future data can be measured the same way and included directly into 
the model. Because the range is similar, plotting graphs will also be easier. When 
both whole blood and intracellular concentrations are in the same graphs it will be 
easier to interpret the plots as well.
 
 
CONCLUSIONS 
 58 
7. CONCLUSIONS 
Re-analyzing for covariates in the whole blood model was performed using the 
traditional forward-inclusion criteria and the backwards-deletion process. The result 
cohered with similar finding in earlier results. This substantiates earlier findings that 
these covariates are relevant for this drug/model.  
Interoccasional variability was included and found significant for V2. With both 
covariates and IOV included, the model for whole blood has improved. The model is 
accurate for low and normal concentrations, but has a tendency to over-predict 
concentrations at the higher end of the scale. The predictions are however stable and 
show little spread.  
A model for whole blood- and intracellular concentration was initially developed 
from the previous model. The model seems capable of predicting different 
concentrations at different sites of measurements. There is generally a better 
prediction of C2-levels compared to C0-levels. The model has however its weaknesses 
however that is quite visible in the 12-hours PK. The absorption phase for both whole 
blood and intracellular concentrations are not optimal and the elimination phase is 
wrongly predicted. There is a need to continue working on the basic model before 
covariates are to be included, IOV have to be checked and finally the model has to be 
validated. 
There are several reasons to continue working on this model. In theory a PPK-model 
will predict concentrations more accurately and stable than in the current clinical 
setting and a prediction of intracellular concentrations may prevent more rejections 
from kidney transplants.
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9. APPENDIX 
9.1 Formulas used in demographics model 
Equation 12: BMI-formula:  
BMI = weight (kg) / (height (m))
2 
 
Equation 13: Hume LBM-formula [60]: 
(Male): L.B.M = 0.32810 W (Weight/kg) + 0.33929 H (Height/cm) – 29.5336  
(Female): L.B.M = 0.29569 W (Weight/kg) + 0.41813 H (Height/cm) – 43.2933 
 
Equation 14: Cockgroft-Gault Equation: 
GFR  =  (140-age(years) x weight (kg)) x (0.85 for women) 
72 x Serum creatinine (mg/dl) 
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9.2 Partial input file for whole blood model 
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9.3 Control file for final model whole blood 
$PROBLEM IOV. 
 
$DATA valider-iov.txt 
 
$INPUT ID AMT RATE=DROP DAT1=DROP TIME C=DV VIST WT UREA=DROP SCR=DROP 
CRCL MDV SS II CMT FLAG=DROP AGE GEN HGHT TXT STER BMI C3A5 LBM 
 
$SUBROUTINE ADVAN4 
 
$PK 
   IF(C3A5.EQ.1) THEN 
   TVCL=THETA(1)-(THETA(8)*CRCL)-(THETA(9)*AGE/56) 
   ELSE 
   TVCL=THETA(7)-(THETA(8)*CRCL)-(THETA(9)*AGE/56) 
   ENDIF 
 
   TVV1=THETA(2)*THETA(10)*BMI/THETA(11)*(AGE/56) 
 
   TVQ=THETA(3)-THETA(12)*(1+STER/100)+THETA(13)*WT 
 
   TVV2=THETA(4) 
 
   TVKA=THETA(5)*THETA(14)**TXT/5*(THETA(15)*BMI)+THETA(16)*AGE/56 
 
   TVALAG=THETA(6) 
 
IOV = ETA(1) 
IF (VIST.EQ.2) IOV = ETA(2) 
IF (VIST.EQ.3) IOV = ETA(3) 
IF (VIST.EQ.4) IOV = ETA(4) 
IF (VIST.EQ.5) IOV = ETA(5) 
IF (VIST.EQ.6) IOV = ETA(6) 
IF (VIST.EQ.7) IOV = ETA(7) 
IF (VIST.EQ.8) IOV = ETA(8) 
IF (VIST.EQ.9) IOV = ETA(9) 
IF (VIST.EQ.10) IOV = ETA(10) 
IF (VIST.EQ.11) IOV = ETA(11) 
 
   CL=TVCL*EXP(ETA(12))             ;Clearance (CL/F) L/hr 
   V1=TVV1*EXP(ETA(13))             ;Central volume (V1/F), L 
   Q=TVQ*EXP(ETA(14))               ;Intercompartmental clearance (Q/F) 
   V2=TVV2*EXP(ETA(15)+IOV)         ;Peripheral volume (V2/F), L 
   KA=TVKA*EXP(ETA(16))             ;Absorption rate constant, 1/hr 
   ALAG1=TVALAG*EXP(ETA(17))        ;Absorption lag time, hr 
 
   S2=V1 
 
   K=CL/V1 
   K23=Q/V1 
   K32=Q/V2 
 
$ERROR 
   IPRED=F 
   Y=F+F*ERR(1)+ERR(2) 
 
$THETA (1,36.6)         ;THETA(1) is POPCL/F on C3A5 
$THETA (15, 21.9, 40)   ;THETA(2) is POPV1/F 
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$THETA (1,18.6)         ;THETA(3) is POPQ/F 
$THETA (1,1200)         ;THETA(4) is POPV2/ 
$THETA (0,0.821,1)      ;THETA(5) is POPKA 
$THETA (0.1,0.452)      ;THETA(6) is POPLAGTIME 
$THETA (1, 38)          ;THETA(7) is POPCL/F on C3A5 
$THETA (0, 0.0047)      ;THETA(8) is CRCL on CL 
$THETA (0, 10.6)        ;THETA(9) is AGE on CL 
$THETA (0, 0.0001)      ;THETA(10)is BMI on V1 
$THETA (0, 0.0012)      ;THETA(11)is AGE on V1 
$THETA (0, 0.0001)      ;THETA(12)is STER on Q 
$THETA (0, 0.001)       ;THETA(13)is WT on Q 
$THETA (0, 0.006)       ;THETA(14)is TXT on ka 
$THETA (0, 265)         ;THETA(15)is BMI on ka 
$THETA (0, 2.1)         ;THETA(16)is AGE on ka 
 
$OMEGA BLOCK(1) 0.1 
$OMEGA BLOCK SAME 
$OMEGA BLOCK SAME 
$OMEGA BLOCK SAME 
$OMEGA BLOCK SAME 
$OMEGA BLOCK SAME 
$OMEGA BLOCK SAME 
$OMEGA BLOCK SAME 
$OMEGA BLOCK SAME 
$OMEGA BLOCK SAME 
$OMEGA BLOCK SAME 
$OMEGA 0.04        ;IIV CL 
$OMEGA 0.01        ;BSVV1/F 
$OMEGA 0.01        ;BSVQ/F 
$OMEGA 2.77        ;BSVV2/F 
$OMEGA 0.563       ;BSVKA 
$OMEGA 0.006       ;BSVALAG1 
 
$SIGMA 0.041     ;ERRCV, Proportional error (%) 
$SIGMA 388       ;ERRSD, Additive error (ug/ml) 
 
$ESTIMATION SIG=3 METHOD=1 INTER MAXEVAL=9999 PRINT=1 POSTHOC NOABORT 
 
$TABLE ID TIME DV IPRED MDV 
NOPRINT ONEHEADER FILE=table.txt 
 
$TABLE ID CL V1 Q V2 KA ALAG1 WT CRCL AGE GEN HGHT TXT STER BMI C3A5 LBM 
FIRSTONLY NOPRINT ONEHEADER NOAPPEND FILE=etatable.txt 
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9.4 Individual fitting made by R for final whole blood model 
Circles: Observed concentrations; Red: Individual post hoc predicted concentrations; 
Blue: Population predicted concentrations. 
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9.5 Partial input file for whole blood and intracellular model 
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9.6 Control file for final model whole blood and intracellular 
concentrations 
$PROBLEM EXAMPLE OF A THREE COMPARTMENT MODEL ABSORPTION INCLUDING 
INTRACELLULAR VALUES AS METABOLITES 
 
$INPUT ID AMT RATE=DROP DAT1=DROP TIME LNDV=DV EVID WT=DROP UREA=DROP 
SCR=DROP CRCL=DROP SS=DROP II=DROP CMT DVID FLAG=DROP AGE=DROP GEN=DROP 
HGHT=DROP TXT=DROP STER=DROP BMI=DROP C3A5=DROP LBM=DROP 
 
$DATA ic.txt 
 
$SUBROUTINES ADVAN6 TOL=4 
 
$MODEL 
 
COMP=(ABSORB) 
COMP=(CENTRAL) 
COMP=(INTRAC) 
COMP=(PERIPH) 
 
$PK 
KA=THETA(1)*EXP(ETA(1)) 
CL2=THETA(2) 
CL3=THETA(3) 
CL4=THETA(4)*EXP(ETA(2)) 
V2=THETA(5) 
V3=THETA(6) 
V4=THETA(7) 
 
K12=KA ; for matrix exponential solution 
K20=CL2/V2 
K23=CL3/V2 
K32=CL3/V3 
K24=CL4/V2 
K42=CL4/V4 
 
S2=V2 
S3=V3 
S4=V4 
 
A_0(2)=0 
A_0(3)=0 
A_0(4)=0 
 
 
$DES 
DADT(1)= -KA*A(1) 
DADT(2)= KA*A(1)-(A(2)*(K20+K23+K24))+A(3)*K32+A(4)*K42 
DADT(3)= A(2)*K23-A(3)*K32 
DADT(4)= A(2)*K24-A(4)*K42 
 
$ERROR 
PLASMA=A(2)/V2 
INTRAC=A(3)/V3 
 
IPRED=A(2)/V2 
IF (DVID.EQ.2) INTRAC=A(3)/V3 
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IPRED=0.001 
IF(F.GT.0) IPRED=LOG(F) 
W=SQRT(THETA(7)**2+THETA(8)**2/(F+0.001)**2) 
IRES=DV-IPRED 
IWRES = IRES/W 
Y=IPRED+W*ERR(1) 
 
$THETA  
(0, 55) 
(0, 3) 
(0, 0.002) 
(0, 0.9) 
(0, 1.5) 
(0, 0.006) 
(0, 17.3) 
(0.3) 
 
$OMEGA 
0.00136 
1 
 
$SIGMA  
0.008 
 
$ESTIMATION SIG=3 METHOD=1 INTER MAXEVAL=9999 PRINT=1 POSTHOC NOABORT 
 
$TABLE ID TIME DV DVID IPRED MDV 
NOPRINT ONEHEADER FILE=table.txt 
 
$TABLE ID CL V1 V2 V3 KA ETA1 ETA2 ETA3 ETA4 ETA5 ETA6 ETA7 WT CRCL FLAG 
AGE GEN HGHT TXT STER BMI C3A5 LBM FIRSTONLY NOPRINT ONEHEADER NOAPPEND 
FILE=etatable.txt 
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9.7 Diagnostic plot made by R for whole blood and 
intracellular model 
Circles: Observed concentrations; Red: Individual post hoc predicted concentrations; 
Blue: Population predicted concentrations. 
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9.8 Diverse figures for whole blood and intracellular model 
with a lower Ka and OFV comparing with the final 
model 
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